Giant Biogene Holding Co., Ltd. (HKG:2367)
Hong Kong · Delayed Price · Currency is HKD 33.48
-0.52 (-1.53%)
At close: Feb 13, 2026
Giant Biogene Holding Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 2,261 | 2,062 | 1,452 | 1,002 | 828.13 | 826.45 |
Depreciation & Amortization | 66 | 48.98 | 33.69 | 27.24 | 23.94 | 22.14 |
Other Amortization | 0.51 | 0.51 | 0.48 | 0.39 | 0.27 | 0.15 |
Loss (Gain) From Sale of Assets | -2.17 | -0.56 | 2.88 | 2.91 | 0.18 | 0.23 |
Loss (Gain) From Sale of Investments | -44.55 | -43.27 | -29.33 | 8.28 | -14.47 | -154.78 |
Loss (Gain) on Equity Investments | 3.67 | 3.6 | - | - | - | - |
Stock-Based Compensation | 66.3 | 89.72 | 20.52 | 17.66 | 16.49 | 0.59 |
Provision & Write-off of Bad Debts | 0.3 | 0.94 | -0.03 | -0.15 | 0.05 | -2.07 |
Other Operating Activities | -107.67 | -94.83 | 39.65 | 4.94 | -104.34 | 16.02 |
Change in Accounts Receivable | -272.35 | -40.2 | -32.58 | -3.64 | -11.16 | -37.51 |
Change in Inventory | -110.56 | -113.51 | -17.77 | -94.36 | -24.61 | -14.44 |
Change in Accounts Payable | -34.42 | 153.6 | 78.46 | 31.04 | -8.33 | 9.17 |
Change in Unearned Revenue | 2.99 | -19.22 | 24.7 | -3.23 | 13.54 | -3.26 |
Change in Other Net Operating Assets | 4.8 | -6.92 | 75.01 | -61.49 | -27.28 | 171.44 |
Operating Cash Flow | 1,834 | 2,041 | 1,647 | 931.64 | 692.4 | 834.12 |
Operating Cash Flow Growth | -2.30% | 23.90% | 76.83% | 34.55% | -16.99% | 27.07% |
Capital Expenditures | -360.2 | -246.77 | -226.3 | -152.66 | -75 | -75.51 |
Divestitures | -0.18 | -3.69 | 33.13 | - | - | - |
Sale (Purchase) of Intangibles | -0.47 | -0.01 | -2.13 | -0.59 | -0.13 | -0.83 |
Sale (Purchase) of Real Estate | - | - | - | - | -19.53 | - |
Investment in Securities | -468.82 | -967 | -379.47 | -718.65 | 1,447 | -686.94 |
Other Investing Activities | 135.75 | 111.35 | 47.49 | 13.16 | 210.72 | 242.16 |
Investing Cash Flow | -688.87 | -1,106 | -527.28 | -858.74 | 1,563 | -521.12 |
Long-Term Debt Repaid | - | -4.18 | -1.05 | -0.19 | - | - |
Net Debt Issued (Repaid) | -5.75 | -4.18 | -1.05 | -0.19 | - | - |
Issuance of Common Stock | 2,170 | 1,504 | 56.4 | 583.51 | 0.06 | - |
Repurchase of Common Stock | - | - | - | -6,236 | - | - |
Common Dividends Paid | -908.44 | -908.44 | - | - | - | - |
Dividends Paid | -908.44 | -908.44 | - | -367.46 | -2,550 | - |
Other Financing Activities | -8.27 | -7.97 | -3.54 | -11.67 | -68.62 | -17.52 |
Financing Cash Flow | 1,248 | 582.95 | 51.81 | -5,790 | 4,476 | -17.52 |
Foreign Exchange Rate Adjustments | -13.56 | 8.18 | 1.09 | -55.18 | 3.98 | - |
Net Cash Flow | 2,379 | 1,526 | 1,173 | -5,772 | 6,735 | 295.48 |
Free Cash Flow | 1,474 | 1,794 | 1,421 | 778.97 | 617.4 | 758.62 |
Free Cash Flow Growth | -11.88% | 26.27% | 82.44% | 26.17% | -18.62% | 32.86% |
Free Cash Flow Margin | 24.12% | 32.40% | 40.33% | 32.95% | 39.77% | 63.72% |
Free Cash Flow Per Share | 1.45 | 1.79 | 1.45 | 0.76 | 0.62 | 0.76 |
Cash Income Tax Paid | 461.22 | 385 | 205.76 | 172.7 | 218.26 | 121.13 |
Levered Free Cash Flow | 1,237 | 1,442 | 1,057 | -6,104 | 5,352 | 2,305 |
Unlevered Free Cash Flow | 1,237 | 1,442 | 1,057 | -6,104 | 5,352 | 2,305 |
Change in Working Capital | -409.54 | -26.24 | 127.81 | -131.67 | -57.85 | 125.39 |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.